Evaluation of anti cancer activity of salicin karanjin and rebaudioside a in breast cancer using experimental model

Abstract

Karanjin significantly lowers cell viability in MCF-7 and MDA-MB-231 cells, as well as being fatal to brine shrimps. These findings suggest that Karanjin may be an effective treatment against breast cancer cells. While Salicin has showed activity in both in vitro and in vivo studies, its activity is lower than that of Karanjin. In any of the experimental models, Rebaudioside-A had no effect on breast cancer. Increased doses of both Karanjin and Salicin had a substantial influence on cell proliferation (MTT assay), cytotoxicity (Brine shrimp test), mitotic reduction (allium Cepa model), cell proliferation (MTT), and anti-tumor efficacy (in vivo). Rebaudioside-A, on the other hand, has no anticancer action.The different treatment groups in this study yielded diverse results. Except for the Rebaudioside-A groups, all treatment groups showed a substantial decline in anti-cancer activity when compared to the negative control. The greatest reduction was reported in the Karanjin 200 mg/kg group, which was nearly equivalent to the positive control. Both Rebaudioside-A groups had no effect as an anti-cancer parameter. newline